3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Melanoma
10
Carcinoma, Renal Cell
9
Kidney Neoplasms
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Leukemia
6
Lymphoma
5
Multiple Myeloma
4
Lymphoma, Follicular
4
Lymphoma, Mantle-Cell
3
Rectal Neoplasms
2
Neoplasms, Plasma Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasms
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Hydroxyurea
8
ruxolitinib
5
Aspirin
3
peginterferon alfa-2b
2
peginterferon alfa-2a
2
liposomal amphotericin B
2
Phlebotomy
2
Early Intervention, Educational
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
pomalidomide
1
givinostat hydrochloride
1
givinostat
1
bomedemstat
1
anagrelide
1
Pipobroman
1
Pharmacogenomic Testing
1
Ondansetron
1
N(4)-oleylcytosine arabinoside
1
Morphine
1
Lenalidomide
1
Ketamine
1
Interferons
1
Interferon-alpha
1
Hypericum extract LI 160
1
Fentanyl
1
Dextromethorphan
1
Caspofungin
1
Asian ginseng
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Polycythemia Vera
×
Interferon-alpha
×
Clear all
NCT04116502
2026-04-28
MITHRIDATE
University of Birmingham
Phase 3
Recruiting
586 enrolled